article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor.

Botox 98
article thumbnail

Ireland is open: The biologics boom boosting the Irish economy

pharmaphorum

The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 AbbVie also presented real-world data on the role of Botox in combination with CGRP mAbs for Chronic Migraine prevention. percent on a reported basis, or 29.6

Botox 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

percent increase since 2021, predominantly due to Botox sales for therapeutic uses. 2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. Botox is also used as therapeutic treatments for neck spasms, excessive sweating, lazy eyes and migraines.

Sales 98